Late Health Outcomes After Contemporary Lymphome Malin de Burkitt Therapy for Mature B-Cell Non-Hodgkin Lymphoma: A Report From the Childhood Cancer Survivor Study

• DOI: 10.1200/jco.19.00525
• Publication Date: 2019-07-08T19:55:26Z
• Authors: Matthew J. Ehrhardt; Yan Chen; John T. Sandlund; Elizabeth C. Bluhm; Robert J. Hayashi; Kerri Becktell; Wendy M. Leisenring; Monika L. Metzger; Kirsten K. Ness; Kevin R. Krull; Kevin C. Oeffinger; Todd M. Gibson; Mitchell S. Cairo; Thomas G. Gross; Leslie L. Robison; Gregory T. Armstrong; Yutaka Yasui; Melissa M. Hudson; Daniel A. Mulrooney
• Keywords: Neurocognitive; Regimen; Late effect

The widely used, risk-based Lymphome Malin de Burkitt (LMB) chemotherapy regimen has improved survival rates for children with mature B-cell non-Hodgkin lymphoma (NHL); however, associated late effects remain understudied. We assessed health outcomes after LMB treatment in the Childhood Cancer Survivor Study.Multivariable regression models compared chronic conditions, status, and socioeconomic neurocognitive between survivors of NHL treated (n = 126), non-LMB regimens 444), siblings 1,029).LMB were a median age 10.2 years (range, 2.5 to 20.5 years) at diagnosis 24.0 10.3 35.3 evaluation. Compared siblings, increased risk adverse outcomes. However, did not differ regard having any impaired deficits, or poorer Increased following specific neurologic conditions was observed survivors: epilepsy (relative [RR], 15.2; 95% CI, 3.1 73.4); balance problems (RR, 8.9; 2.3 34.8); tremors 7.5; 1.9 29.9); weakness legs 8.1; 26.4); severe headaches 3.2; 1.6 6.3); prolonged arm, leg, back pain 4.0; 2.2 7.1). from group C 50) highest these conditions; except worse functional status (odds ratio, 2.7; 1.2 5.8), they other survivors.Survivors are largely comparable excess neurotoxicity among survivors. These data inform efforts seeking optimize disease control while minimizing toxicity.